CN103191140A - 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 - Google Patents
大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 Download PDFInfo
- Publication number
- CN103191140A CN103191140A CN2013100873836A CN201310087383A CN103191140A CN 103191140 A CN103191140 A CN 103191140A CN 2013100873836 A CN2013100873836 A CN 2013100873836A CN 201310087383 A CN201310087383 A CN 201310087383A CN 103191140 A CN103191140 A CN 103191140A
- Authority
- CN
- China
- Prior art keywords
- glucoside
- emodin
- cell
- beta
- tumor activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZXXFEBMBNPRRSI-UHFFFAOYSA-N 3'-Prenyl-4'-methoxy-isoflavone-7-O'-??-D-(2''-O-p-coumaroyl)glycopyranoside Natural products C=12C(=O)C3=C(O)C=C(O)C=C3C(=O)C2=CC(C)=CC=1OC1OC(CO)C(O)C(O)C1O ZXXFEBMBNPRRSI-UHFFFAOYSA-N 0.000 title claims abstract description 50
- HSWIRQIYASIOBE-UHFFFAOYSA-N Emodin-8-O-beta-D-glucosid Natural products C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O HSWIRQIYASIOBE-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 14
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 201000007270 liver cancer Diseases 0.000 claims abstract description 3
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 11
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000010282 Emodin Substances 0.000 claims description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 2
- 230000001644 anti-hepatocarcinoma Effects 0.000 claims description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 230000001629 suppression Effects 0.000 description 13
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- JAABVEXCGCXWRR-UHFFFAOYSA-N norcantharidin Chemical compound C1CC2C3C(=O)OC(=O)C3C1O2 JAABVEXCGCXWRR-UHFFFAOYSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001249696 Senna alexandrina Species 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 241000123835 Ampelopsis japonica Species 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 241001646826 Isodon rubescens Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 240000007001 Rumex acetosella Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310087383.6A CN103191140B (zh) | 2013-03-19 | 2013-03-19 | 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310087383.6A CN103191140B (zh) | 2013-03-19 | 2013-03-19 | 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103191140A true CN103191140A (zh) | 2013-07-10 |
CN103191140B CN103191140B (zh) | 2015-04-01 |
Family
ID=48714076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310087383.6A Active CN103191140B (zh) | 2013-03-19 | 2013-03-19 | 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103191140B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103845420A (zh) * | 2014-02-26 | 2014-06-11 | 东南大学 | 一种塔黄提取物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101362702A (zh) * | 2008-09-12 | 2009-02-11 | 南昌大学 | 大黄素衍生物及其在制备抗癌药物中的应用 |
CN102391095A (zh) * | 2011-08-11 | 2012-03-28 | 四川大学华西医院 | 大黄素衍生物及其用途 |
-
2013
- 2013-03-19 CN CN201310087383.6A patent/CN103191140B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101362702A (zh) * | 2008-09-12 | 2009-02-11 | 南昌大学 | 大黄素衍生物及其在制备抗癌药物中的应用 |
CN102391095A (zh) * | 2011-08-11 | 2012-03-28 | 四川大学华西医院 | 大黄素衍生物及其用途 |
Non-Patent Citations (1)
Title |
---|
NAM-JAE LEE,等: "Antimutagenicity and Cytotoxicity of the Constituents from the Aerial Parts of Rumex acetosa", 《BIOL. PHARM. BULL.》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103845420A (zh) * | 2014-02-26 | 2014-06-11 | 东南大学 | 一种塔黄提取物及其应用 |
CN103845420B (zh) * | 2014-02-26 | 2016-03-16 | 东南大学 | 一种塔黄提取物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103191140B (zh) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
An et al. | Apoptotic pathway as the therapeutic target for anticancer traditional Chinese medicines | |
Zhang et al. | Natural product interventions for chemotherapy and radiotherapy-induced side effects | |
Tavakoli et al. | Evaluation of effectiveness of herbal medication in cancer care: a review study | |
Yang et al. | Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis | |
Islam | Diterpenes and their derivatives as potential anticancer agents | |
Kapadia et al. | Synergistic cytotoxicity of red beetroot (Beta vulgaris L.) extract with doxorubicin in human pancreatic, breast and prostate cancer cell lines | |
CN1874781B (zh) | 用于癌症治疗的植物提取物的组合物 | |
Chen et al. | FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review | |
Asadi‐Samani et al. | Inhibition of Th1 and Th17 cells by medicinal plants and their derivatives: a systematic review | |
Yang et al. | Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case–control study | |
Wu et al. | A review of complementary therapies with medicinal plants for chemotherapy-induced peripheral neuropathy | |
Xiao et al. | Review of the use of botanicals for epilepsy in complementary medical systems—Traditional Chinese Medicine | |
Pandith et al. | Evaluation of anthraquinones from Himalayan rhubarb (Rheum emodi Wall. ex Meissn.) as antiproliferative agents | |
Liu et al. | Cardiotoxicity of doxorubicin-based cancer treatment: What is the protective cognition that phytochemicals provide us? | |
Xia et al. | A map describing the association between effective components of traditional Chinese medicine and signaling pathways in cancer cells in vitro and in vivo | |
Wu et al. | Regulatory role of chinese herbal medicine in regulated neuronal death | |
Suzuki et al. | Effect of ninjin’yoeito and ginseng extracts on oxaliplatin-induced neuropathies in mice | |
Behravan et al. | Review of plants and their constituents in the therapy of cerebral ischemia | |
Li et al. | In vitro antioxidant, immunomodulatory and anticancer activities of two fractions of aqueous extract from Helicteres angustifolia L. root | |
Wang et al. | Overcoming chemotherapy resistance with herbal medicines: past, present and future perspectives | |
Wan et al. | Red American ginseng enhances the effect of fluorouracil on human colon cancer cells via both paraptosis and apoptosis pathways | |
US9789153B2 (en) | Composition for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs | |
Song et al. | Traditional Chinese medicine for treatment of sepsis and related multi-organ injury | |
CN103191140B (zh) | 大黄素-8-O-β-D-葡萄糖苷的抗肿瘤活性及其新用途 | |
CN102872385B (zh) | 一种治疗晚期胃癌的复方中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Zhenxiao Inventor after: Li Dengke Inventor after: Li Baosai Inventor after: Wang Rufeng Inventor before: Sun Zhenxiao Inventor before: Li Baosai Inventor before: Wang Rufeng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SUN ZHENXIAO LI BAOSAI WANG RUFENG TO: SUN ZHENXIAO LI DENGKE LI BAOSAI WANG RUFENG |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Sun Zhenxiao Document name: Notification to Pay the Fees |
|
CP02 | Change in the address of a patent holder |
Address after: 102488 Liangxiang University Town, Fangshan District, Beijing Patentee after: Sun Zhenxiao Address before: 100102 Department of Biopharmaceutics, School of Chinese Materia Medica, Beijing University of Chinese Medicine, 6 South Central Road, Wangjing, Beijing, Chaoyang District Patentee before: Sun Zhenxiao |
|
CP02 | Change in the address of a patent holder |